Evaluates sulbactam-durlobactam's effectiveness against carbapenem-resistant Acinetobacter in Brazil, suggesting a viable treatment option.
Carbapenem-resistant Acinetobacter baumannii (CRAb) causes high-mortality infections, with limited treatment options. We evaluated sulbactam-durlobactam activity against 94 isolates from Brazil. Durlobactam markedly reduced sulbactam MICs, restoring susceptibility in all CRAb. They belonged to seven STs, mainly ST730 and ST79. Despite genetic and phenotypic diversity, including distinct carbapenemase genes (particularly bla OXA-23-like ) and the presence of PBP3 mutations, activity remained consistent. These findings support sulbactam-durlobactam as an effective option against CRAb in this high-endemic setting.
No takes yet. Share an insight, caveat, or question.
Collar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: